image credit: Unsplash

Moderna inks second genetic medicine deal in a month

March 23, 2023

Moderna, flush with more than $18 billion in cash at the end of 2022 from revenue generated by its COVID-19 vaccine, has been reinvesting some of that money in search of its next growth engine. This year, the company is ramping up spending on research and development to $4.5 billion.

Increasingly, Moderna is exploring gene-based medicines and different applications of its experience with messenger RNA and lipid nanoparticles, the fatty spheres used to deliver its COVID-19 shot.

Read More on Biopharma Dive